Update 2025: GLP-1 Medications in Diabetes, Obesity and Beyond

 Presenters

Headshot of Brian Rodrigues.

Dr. Brian Rodrigues
BSc, MSc (UBC), PhD
Professor, University of British Columbia

Dr. Brian Rodrigues is a Full Professor in the Faculty of Pharmaceutical Sciences, with over 35 years of research experience and 20 teaching awards. His research program examines the mechanism of how fat fuels are provided to the heart and how excess fats can lead to cardiac disease following diabetes. The purpose of the research is to enable the identification of novel targets for therapeutic intervention to prevent heart failure during diabetes. Funds for his research are currently provided by the Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, and Diabetes Canada.

Headshot of Rui Shang.

Dr. Rui Shang
Post Doctoral Fellow
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital

Dr. Rui Shang completed her bachelor's degree at the Tsukuba University in Japan. She joined Dr. Rodrigues’ lab at UBC and completed her PhD in cardiac metabolism in 2023. She then joined Dr. Dan Drucker’s lab as a Postdoctoral Fellow where she is currently studying incretin-based therapies for cardiovascular complications associated with obesity and diabetes.

Session Information

Description

This session will cover the general overview of glucagon-like peptide 1 (GLP-1) biology under the context of diabetes and obesity. We will discuss different GLP-1 receptor agonists (GLP-1RAs), especially those related to their mechanism of action on glycemic control and weight reduction. Attendees will learn the latest findings of ongoing or recently completed clinical trials using drugs within this class in metabolic complications associated with diabetes and obesity along with their side effects. Finally, this session will explore the ongoing development in GLP-1-based co-agonist and combination therapies.

Learning Objectives
  • Review glucagon-like peptide 1 (GLP-1) biology. 
  • Describe the mechanism of action of GLP-1RAs. 
  • Recognize the therapeutic potential of GLP-1RAs in metabolic complications associated with diabetes and obesity. 
  • Identify ongoing development in GLP-1-based co-agonist and combination therapies.

Faculty of Pharmaceutical Sciences

2405 Wesbrook Mall
Vancouver, BC Canada
V6T 1Z3
info.pharmsci@ubc.ca

UBC Crest The official logo of the University of British Columbia. Urgent Message An exclamation mark in a speech bubble. Arrow An arrow indicating direction. Arrow in Circle An arrow indicating direction. Arrow in Circle An arrow indicating direction. Caret An arrowhead indicating direction. Chats Two speech clouds. Facebook The logo for the Facebook social media service. Fax A lineart image of a fax machine. Information The letter 'i' in a circle. Instagram The logo for the Instagram social media service. Linkedin The logo for the LinkedIn social media service. Location Pin A map location pin. Mail An envelope. Menu Three horizontal lines indicating a menu. Minus A minus sign. Telephone An antique telephone. Plus A plus symbol indicating more or the ability to add. Print A lineart image of a printer. Search A magnifying glass. Twitter The logo for the Twitter social media service. X The logo for the X social media service. Youtube The logo for the YouTube video sharing service.